Monoclonal antibodies are a >US$70bn drug class. This Aussie company is set to revolutionise that market

Stuart Roberts

Pitt Street Research and NDF Research

AT NDF Research we love being the first to cover promising Life Sciences companies. Today we're initiating on AdAlta, a Melbourne-based drug developer that did its IPO last month with Platinum Asset Management as a substantial shareholder. AdAlta is focused on a new class of protein therapeutic called the i-body. Monoclonal antibodies are a workhorse of modern medicine with global sales of >$US70bn pa. But they are expensive to make and their molecule size makes them too big for use against many important drug targets. They also require heavy dosing and this must be delivered by intravenous infusion. AdAlta's antibody-like drugs, called i-bodies, have the same target specificity and affinity as monoclonal antibodies, but are about 90% smaller. They will also likely be cheaper to make, easier to administer and capable of addressing difficult-to-treat diseases such as fibrosis. We see considerable upside for AdAlta given the high valuation that validated antibody and antibody-like platforms tend to trade for. Like a Belgian company called Ablynx, market cap US$770m. At the moment you can get AdAlta for just A$24. Visit (VIEW LINK)


Stuart Roberts
Founder and Senior Analyst
Pitt Street Research and NDF Research

I am an equity research professional who worked in stockbroking from 2001 to 2015. After 15 months doing investor relations I returned to equity research with the founding of NDF Research. With Marc Kennis I founded Pitt Street Research in July 2018.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.